Bruker Corporation (NASDAQ:BRKR) – Research analysts at Jefferies Group decreased their Q3 2017 earnings per share estimates for Bruker Corporation in a research report issued on Friday. Jefferies Group analyst B. Couillard now expects that the medical research company will post earnings of $0.26 per share for the quarter, down from their previous estimate of $0.27. Jefferies Group currently has a “Buy” rating and a $29.00 target price on the stock. Jefferies Group also issued estimates for Bruker Corporation’s Q4 2017 earnings at $0.44 EPS, FY2017 earnings at $1.11 EPS, Q2 2018 earnings at $0.32 EPS, Q3 2018 earnings at $0.33 EPS, Q4 2018 earnings at $0.38 EPS and FY2018 earnings at $1.32 EPS.

Several other equities research analysts have also commented on the stock. BidaskClub lowered shares of Bruker Corporation from a “strong-buy” rating to a “buy” rating in a report on Friday, July 28th. Barclays PLC reaffirmed an “equal weight” rating and issued a $30.00 price target (up from $26.00) on shares of Bruker Corporation in a report on Monday, July 17th. Cowen and Company reissued a “hold” rating and set a $29.00 target price on shares of Bruker Corporation in a research note on Friday, July 14th. Wells Fargo & Company lowered shares of Bruker Corporation from a “market perform” rating to an “underperform” rating in a research note on Wednesday, July 12th. Finally, Zacks Investment Research raised shares of Bruker Corporation from a “hold” rating to a “buy” rating and set a $33.00 target price on the stock in a research note on Thursday, July 6th. One analyst has rated the stock with a sell rating, eight have given a hold rating and five have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $27.00.

WARNING: “Bruker Corporation to Post Q3 2017 Earnings of $0.26 Per Share, Jefferies Group Forecasts (NASDAQ:BRKR)” was first published by Daily Political and is the property of of Daily Political. If you are viewing this news story on another site, it was stolen and reposted in violation of international trademark & copyright law. The original version of this news story can be read at https://www.dailypolitical.com/2017/08/07/bruker-corporation-to-post-q3-2017-earnings-of-0-26-per-share-jefferies-group-forecasts-nasdaqbrkr.html.

Shares of Bruker Corporation (NASDAQ:BRKR) opened at 27.88 on Monday. The company has a market capitalization of $4.45 billion, a PE ratio of 29.60 and a beta of 1.10. The firm’s 50-day moving average price is $28.70 and its 200-day moving average price is $25.43. Bruker Corporation has a 12-month low of $19.58 and a 12-month high of $30.22.

Bruker Corporation (NASDAQ:BRKR) last posted its quarterly earnings results on Thursday, August 3rd. The medical research company reported $0.23 EPS for the quarter, beating the Zacks’ consensus estimate of $0.20 by $0.03. The business had revenue of $414.90 million for the quarter, compared to analysts’ expectations of $384.75 million. Bruker Corporation had a return on equity of 27.18% and a net margin of 9.65%. The business’s quarterly revenue was up 11.6% on a year-over-year basis. During the same period last year, the firm earned $0.20 earnings per share.

Bruker Corporation declared that its Board of Directors has authorized a share buyback plan on Friday, May 12th that authorizes the company to repurchase $225.00 million in outstanding shares. This repurchase authorization authorizes the medical research company to repurchase shares of its stock through open market purchases. Shares repurchase plans are generally a sign that the company’s management believes its stock is undervalued.

In related news, CEO Frank H. Laukien purchased 73,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 18th. The shares were purchased at an average cost of $26.22 per share, with a total value of $1,914,060.00. Following the purchase, the chief executive officer now owns 37,750,851 shares of the company’s stock, valued at approximately $989,827,313.22. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Ingen Chris Van sold 19,900 shares of the firm’s stock in a transaction dated Wednesday, June 14th. The shares were sold at an average price of $28.03, for a total transaction of $557,797.00. Following the completion of the transaction, the director now directly owns 14,577 shares in the company, valued at $408,593.31. The disclosure for this sale can be found here. Over the last three months, insiders have bought 78,120 shares of company stock worth $2,047,366 and have sold 117,624 shares worth $3,271,574. Corporate insiders own 35.20% of the company’s stock.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Alps Advisors Inc. raised its position in shares of Bruker Corporation by 0.3% in the second quarter. Alps Advisors Inc. now owns 20,154 shares of the medical research company’s stock worth $581,000 after buying an additional 52 shares in the last quarter. Federated Investors Inc. PA raised its position in shares of Bruker Corporation by 0.3% in the second quarter. Federated Investors Inc. PA now owns 60,553 shares of the medical research company’s stock worth $1,746,000 after buying an additional 204 shares in the last quarter. Public Employees Retirement System of Ohio raised its position in shares of Bruker Corporation by 0.7% in the first quarter. Public Employees Retirement System of Ohio now owns 48,267 shares of the medical research company’s stock worth $1,126,000 after buying an additional 312 shares in the last quarter. Denver Investment Advisors LLC raised its position in shares of Bruker Corporation by 7.2% in the first quarter. Denver Investment Advisors LLC now owns 22,215 shares of the medical research company’s stock worth $518,000 after buying an additional 1,500 shares in the last quarter. Finally, Aperio Group LLC raised its position in shares of Bruker Corporation by 9.6% in the second quarter. Aperio Group LLC now owns 19,362 shares of the medical research company’s stock worth $558,000 after buying an additional 1,699 shares in the last quarter. 67.00% of the stock is currently owned by hedge funds and other institutional investors.

Bruker Corporation Company Profile

Bruker Corporation designs and manufactures scientific instruments, and analytical and diagnostic solutions. Its segments include the Bruker BioSpin Group; the Bruker Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID) Group; the Bruker Nano Group, and the Bruker Energy & Supercon Technologies (BEST) Segment.

Earnings History and Estimates for Bruker Corporation (NASDAQ:BRKR)

Receive News & Ratings for Bruker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker Corporation and related companies with MarketBeat.com's FREE daily email newsletter.